AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The COVID-19 vaccine co-developed by AstraZeneca and University of Oxford was 79% effective at protecting against coronavirus in the vaccine's largest trial yet, the drugmaker said on Monday. The drugmaker can now submit the data from the trial to be scrutinized by the US regulator, the Food and Drug Administration.

AstraZeneca's COVID-19 shot was 79% effective in large trial, paving the way for approval in the US despite troubles in Europe

The coronavirus vaccine developed by AstraZeneca and the University of Oxford has been found to be 79% effective in a large U.S. trial.

AstraZeneca coronavirus vaccine found to be 79% effective in U.S. trial

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AstraZeneca To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - March 21, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN) and reminds investors of the March 29, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you suffered losses exceeding $50,000 investing in AstraZeneca stock or options between May 21,...

Astrazeneca Update

BioNTech SE

Johnson & Johnson

Moderna

Novavax

Pfizer

Some stocks could be big winners and losers depending on what the answer to this question is.

The Multibillion-Dollar Question: How Long Do COVID Vaccines Last?

NEW YORK, March 20, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline. SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AZN INVESTOR ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important March 29 Deadline in Securities Class Action - AZN

Boston, Massachusetts--(Newsfile Corp. - March 20, 2021) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of AstraZeneca PLC (NASDAQ: AZN). The case is currently in the lead plaintiff stage. Investors who purchased AZN stock or other securities between May 21, 2020 and November 20, 2020 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/AstraZeneca to submit their information. Investors may also...

AstraZeneca Investor Alert: Shareholder Lawsuit Filed

Isolating the cause has allowed scientists to develop a treatment for the blot clots once diagnosed.

European Scientists Say They Know Why AstraZeneca's Vaccine Is Causing Rare Blood Clots

Finland investigates possible blood clots as others in Europe resume AstraZeneca Covid-19 shots and France is forced into new lockdowns.

Nordic Countries Outliers as Europe Resumes Use of AstraZeneca Shot

The panel said AstraZeneca's coronavirus vaccine had “tremendous potential” to prevent cases and deaths, reaffirming support for the shot after concerns over blood clots prompted some European nations to temporarily suspend use of it.

WHO Stands Behind AstraZeneca Coronavirus Vaccine After Blood Clot Concerns

France has changed its guidance on the shot three, initially restricting it to those under 65 years of age.

Europe's Flip-Flopping Over AstraZeneca's Covid-19 Vaccine Continues: France Ignores Regulator And Limits Shot To Over-55s

The French government announced on Thursday that the whole greater Paris region will be placed under lockdown, forcing President Emmanuel Macron to backtrack on his insistence that such strict measures could be avoided.

Europe resumes using AstraZeneca shots as France is forced into new lockdowns

An analyst has a suggestion for AstraZeneca PLC (NASDAQ:AZN) shareholders concerned about negative publicity about the company's Covid vaccine: relax.

Analysts: Focus on AstraZeneca's Positives, Not Vaccine Issue

After more than a dozen countries paused the use of AstraZeneca's coronavirus vaccine due to concerns about blood clots, the European Medicines Agency concluded on Thursday that the vaccine doesn't increase the risk of clotting. The World Health Organization, too, recommended that countries continue to administer AstraZeneca's vaccine, since the benefits of the shot "outweigh its risks."

The US hasn't authorized AstraZeneca's vaccine for 2 main reasons. That could change in April.

The vaccine is not associated with an increase in the overall risk of blood clots, the European Medicines Agency found.

AstraZeneca's COVID vaccine is safe, says European regulator after blood clot concerns

The European Medicines Agency said the benefits of the Covid-19 vaccine outweighed the possible risks, in a press briefing on Thursday.

EU Regulator Says AstraZeneca Vaccine Is ‘Safe and Effective' After Blood Clot Investigation

The U.S. is planning to send 4 million doses of the AstraZeneca COVID-19 vaccine to Mexico and Canada, the White House said Thursday. White House press secretary Jen Psaki described the arrangements as loans, with 2.5 million doses going to Mexico and 1.5 million doses for Canada.

U.S. plans to send AstraZeneca vaccine doses to Canada, Mexico: White House

The agency said it was unable to decisively rule out a link between some extremely rare blood clotting events and the vaccine but felt the benefits of getting vaccinated outweighed the risks.

EU Agency OKs AstraZeneca Vaccine Ruling Out Broad Link To Blood Clotting

Finally, the much-awaited safety review of blood clot reports is now complete and the European Medicines Agency (EMA) concluded that AstraZeneca Plc's (NASDAQ: AZN) COVID vaccine is "safe and effective". What Happened: The highly anticipated opinion comes at a time when the European Union is witnessing a vaccine shortage, and the bloc is suffering yet another surge in COVID-19 infection cases.

EMA 'Firmly Convinced' With Benefits Of AstraZeneca Vaccine Exceeding Risks: Report

Europe's regulator has concluded that the AstraZeneca COVID-19 vaccine is "safe and effective," following its investigation into reports of blood clots in people that had received the shot.

EU regulator says AstraZeneca vaccine is safe and effective after blood clot investigation.

AstraZeneca and Oxford University's COVID-19 vaccine is safe and its benefits clearly outweigh its risks, the European regulator said Thursday. The European Medicines Agency (EMA) said in a press briefing that AstraZeneca's vaccine was not associated with higher levels of blood clots, following a investigation into reports that people who had received the vaccine developed clots.

AstraZeneca's vaccine is safe, Europe's regulator said following an investigation into potential side effects. 18 countries could now lift their suspensions of the shot.

AstraZeneca stock remained under pressure Thursday as European medical regulators met to discuss the company's Covid-19 vaccine amid increasing concerns of blood clots. The post AstraZeneca Under Pressure As Its Covid Vaccine Faces Another Challenge appeared first on Investor's Business Daily.

AstraZeneca Under Pressure As Its Covid Vaccine Faces Another Challenge

The EMA said Thursday that the benefits of the vaccine outweighed the risks.

European regulator greenlights AstraZeneca coronavirus vaccine after reports of blood clots

The European Commission will send a letter to AstraZeneca as the first step of efforts to resolve a dispute with the company over its supplies of COVID-19 vaccines to the bloc, Reuters reports. What Happened: Yesterday, European Commission's President Ursula von der Leyen threatened to stop vaccine exports to safeguard scarce doses unless the U.K. starts shipping shots to the bloc.

AstraZeneca Set To Get Letter From EU As First Step Of Legal Action For Delayed Deliveries: Reuters

Los Angeles, California--(Newsfile Corp. - March 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC (NASDAQ: AZN) ("AstraZeneca" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the ''Class Period''),...

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Goldman Sachs analysts said Europe's strong growth rebound wouldn't be derailed, whatever the outcome from the EU's drug regulator on Thursday.

News for AstraZeneca Stock (AZN)